Sofinnova Partners closes oversubscribed Fund XI at €650m

The European early-stage life sciences investor’s flagship fund will focus on biotech and medtech start-ups across Europe and North America.

17 November 2025•2 mins read
LinkedInXEmail
LinkedInXEmail

Related articles